Exploration and optimisation of structure-activity relationships of new triazole-based C-terminal Hsp90 inhibitors towards in vivo anticancer potency.

Cancer Ewing sarcoma Hsp90 Inhibitor Zebrafish

Journal

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295

Informations de publication

Date de publication:
17 Jun 2024
Historique:
received: 31 01 2024
revised: 30 05 2024
accepted: 10 06 2024
medline: 19 6 2024
pubmed: 19 6 2024
entrez: 18 6 2024
Statut: aheadofprint

Résumé

The development of new anticancer agents is one of the most urgent topics in drug discovery. Inhibition of molecular chaperone Hsp90 stands out as an approach that affects various oncogenic proteins in different types of cancer. These proteins rely on Hsp90 to obtain their functional structure, and thus Hsp90 is indirectly involved in the pathophysiology of cancer. However, the most studied ATP-competitive inhibition of Hsp90 at the N-terminal domain has proven to be largely unsuccessful clinically. Therefore, research has shifted towards Hsp90 C-terminal domain (CTD) inhibitors, which are also the focus of this study. Our recent discovery of compound C has provided us with a starting point for exploring the structure-activity relationship and optimising this new class of triazole-based Hsp90 inhibitors. This investigation has ultimately led to a library of 33 analogues of C that have suitable physicochemical properties and several inhibit the growth of different cancer types in the low micromolar range. Inhibition of Hsp90 was confirmed by biophysical and cellular assays and the binding epitopes of selected inhibitors were studied by STD NMR. Furthermore, the most promising Hsp90 CTD inhibitor 5x was shown to induce apoptosis in breast cancer (MCF-7) and Ewing sarcoma (SK-N-MC) cells while inducing cause cell cycle arrest in MCF-7 cells. In MCF-7 cells, it caused a decrease in the levels of ERα and IGF1R, known Hsp90 client proteins. Finally, 5x was tested in zebrafish larvae xenografted with SK-N-MC tumour cells, where it limited tumour growth with no obvious adverse effects on normal zebrafish development.

Identifiants

pubmed: 38889640
pii: S0753-3322(24)00825-4
doi: 10.1016/j.biopha.2024.116941
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

116941

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Jaka Dernovšek (J)

Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, Ljubljana 1000, Slovenia.

Živa Zajec (Ž)

Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, Ljubljana 1000, Slovenia.

Goran Poje (G)

Faculty of Pharmacy and Biochemistry, University of Zagreb, Ante Kovačića 1, Zagreb 10000, Croatia.

Dunja Urbančič (D)

Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, Ljubljana 1000, Slovenia.

Caterina Sturtzel (C)

St. Anna Children's Cancer Research Institute, Zimmermannplatz 10, Vienna 1090, Austria.

Tjaša Goričan (T)

Laboratory for Molecular Structural Dynamics, Theory Department, National Institute of Chemistry, Hajdrihova 19, Ljubljana 1001, Slovenia.

Sarah Grissenberger (S)

St. Anna Children's Cancer Research Institute, Zimmermannplatz 10, Vienna 1090, Austria.

Krzesimir Ciura (K)

Department of Physical Chemistry, Medical University of Gdańsk, Gdańsk 80-416, Poland.

Mateusz Woziński (M)

Department of Physical Chemistry, Medical University of Gdańsk, Gdańsk 80-416, Poland.

Marius Gedgaudas (M)

Department of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Saulėtekio al. 7, Vilnius LT-10257, Lithuania.

Asta Zubrienė (A)

Department of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Saulėtekio al. 7, Vilnius LT-10257, Lithuania.

Simona Golič Grdadolnik (SG)

Laboratory for Molecular Structural Dynamics, Theory Department, National Institute of Chemistry, Hajdrihova 19, Ljubljana 1001, Slovenia.

Irena Mlinarič-Raščan (I)

Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, Ljubljana 1000, Slovenia.

Zrinka Rajić (Z)

Faculty of Pharmacy and Biochemistry, University of Zagreb, Ante Kovačića 1, Zagreb 10000, Croatia.

Andrej Emanuel Cotman (AE)

Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, Ljubljana 1000, Slovenia.

Nace Zidar (N)

Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, Ljubljana 1000, Slovenia.

Martin Distel (M)

St. Anna Children's Cancer Research Institute, Zimmermannplatz 10, Vienna 1090, Austria.

Tihomir Tomašič (T)

Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, Ljubljana 1000, Slovenia. Electronic address: tihomir.tomasic@ffa.uni-lj.si.

Classifications MeSH